Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Precision Medicine for Lupus Continues to Progress

Thomas R. Collins  |  Issue: June 2018  |  June 21, 2018

HelloRF Zcool / shutterstock.com

HelloRF Zcool / shutterstock.com

CHICAGO—The promise of precision medicine—the tailoring of treatment to a given patient based on genetics and other factors—has probably been best illustrated in oncology, with therapies targeted specifically to markers expressed on tumors. But rheumatology is in the thick of precision medicine as well, said Judith James, MD, PhD, chair of the arthritis and clinical immunology program at the Oklahoma Medical Research Foundation in Oklahoma City.

Compared with other specialties, rheumatology has historically had the highest number of biomarker tests approved by the U.S. Food & Drug Administration, mainly because so many autoantibody tests are used. At the ACR State-of-the-Art Clinical Symposium in April, Dr. James showed how new lupus research is attempting to fuse genetics and other data into practical information that can be used patient-by-patient in the clinic.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lupus Subsets

This will benefit patients across the rheumatology sphere, but especially in systemic lupus erythematosus (SLE), which manifests in many ways. In the same waiting room, Dr. James said, one patient could mainly suffer from fatigue that makes daily errands difficult, while another’s kidneys have shut down, forcing them onto dialysis.

“The big challenge in lupus is that we have a lot of heterogeneity,” she said. “We hope we can start taking lupus patients and finding different subsets.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In one of the largest genetic lupus studies published last year, 50,000 unique parts of the genome were interrogated in 27,000 people, including patients and controls.1 Genetic associations, such as tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), signal transducer and activator of transcription 4 (STAT4) and tyrosine kinase 2 (TYK2), were identified. And Dr. James said researchers are also beginning to see novel associations in African-Americans and Hispanics that haven’t been seen before.

“We have identified genetic associations that may account for more than 50% of the heritable risk of lupus among patients of European-American descent based upon these studies and the other published data,” she said.

But genetics tell only part of the story, she said.

“Genetics are usually what we think of with precision medicine,” she said. “I think that what we’re learning from the genetics in our diseases is that genetics alone are probably not going to be all we need to be able to inform us about how to treat our patients.”

In studies based on the Dallas Pediatric SLE Cohort, clinical and blood transcriptional profiles were collected from 158 pediatric patients and 48 healthy controls over time for up to four years, with SLE Disease Activity Index components and medication use recorded for every visit.2 (The Dallas group has modules available that allow clinicians from elsewhere to enter data from their own patients to see their risk of flare.)

Dr. James

‘We have identified genetic associations that may account for more than 50% of the heritable risk of lupus among patients of European-American descent.’ —Dr. James

They found the interferon gene signature was present in 85% of the pediatric lupus patient samples, but in only 15% of samples from healthy children. They also identified 486 transcripts that were most correlated with disease activity, as well as a neutrophil gene signature strongly linked with lupus nephritis.

At Dr. James’ center, researchers have been looking at adult lupus, attempting to use clinical features, gene expression profiling, soluble mediators, autoantibodies and immunophenotyping to try to split patients into subgroups that will characterize them more specifically compared to the general lupus population. Among their findings, patients who were early to flare had elevated CD11b(high) monocytes and elevated CD86(high) B cells, and one group featured more kidney disease than other groups.

Dr. James said some of the same clinical features were seen in different molecular subgroups. “That may suggest that patients get to the same clinical phenotype but through different molecular pathways, which may be important [because] we’re trying to select the right medication for the right patient,” she said.

Despite the progress in trying to treat at the individual patient level, some improvements are needed in rheumatology to take the next steps. “We need more systems biology … approaches to take all of this collective information and distill it into things we can use practically for an individual patient on a given day,” she said.

More effective collaborations are needed as well, Dr. James continued. “And we’re going to need different types of interaction with different kinds of health professionals who we haven’t historically used in rheumatology, like molecular pathologists, who are really focused on the genetic information.”

She mentioned many “huge” precision medicine programs are underway—e.g., the National Institutes of Medicine All of Us Precision Medicine Initiative and the Million Veteran Program—that plan to enroll a million Americans for whole genome sequencing.

“You will see more and more patients [with] the sequencing data.”


Thomas R. Collins is a freelance writer living in South Florida.

References

  1. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017 Jul 17;8:16021.
  2. Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016 Apr 21;165(3):551–565.

Page: 1 2 | Multi-Page
Share: 

Filed under:Meeting ReportsSystemic Lupus Erythematosus Tagged with:2018 State of the Art Clinical SymposiumLupusPrecision Medicine

Related Articles

    Experts Discuss the Latest Precision Medicine Research

    February 18, 2018

    Eetu Mustonen / SHUTTERSTOCK.COM SAN DIEGO—In just two decades, precision medicine has gone from futuristic concept to realistic toolbox for clinical physicians. At the 2017 ACR Clinical Research Conference on Nov. 3, the Precision Medicine in Rheumatic Diseases: Hopes and Challenges lecture featured rheumatologists and experts on genetics, genomics, pharmaco­genetics and big data who spoke…

    Genome-Wide Association Studies of SLE

    February 12, 2011

    What do these studies tell us about disease mechanisms in lupus?

    Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

    February 25, 2020

    How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…

    Lupus often presents with a butterfly rash.

    Top 12: Research in Systemic Lupus Erythematosus at a Glance

    November 18, 2021

    Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences